BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 28410844)

  • 21. The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients.
    Dehghani M; Keshavarz P; Talei A; Akrami M; Tahmasebi S; Safaie A; Ghanbari M
    Asian Pac J Cancer Prev; 2020 Oct; 21(10):3027-3032. PubMed ID: 33112563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
    Tzikas AK; Nemes S; Linderholm BK
    Breast Cancer Res Treat; 2020 Aug; 182(3):643-654. PubMed ID: 32524352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    Chen LL; Zhang ZJ; Yi ZB; Li JJ
    Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India.
    Chandra D; Suresh P; Sinha R; Azam S; Batra U; Talwar V; Kumar K; Mehta A
    Asian Pac J Cancer Prev; 2016; 17(6):2995-9. PubMed ID: 27356724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis.
    Park S; Park JM; Cho JH; Park HS; Kim SI; Park BW
    Ann Surg Oncol; 2013 Sep; 20(9):2858-65. PubMed ID: 23645483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
    Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
    Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.
    Ricciardi GR; Adamo B; Ieni A; Licata L; Cardia R; Ferraro G; Franchina T; Tuccari G; Adamo V
    PLoS One; 2015; 10(6):e0128368. PubMed ID: 26039245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.
    Chang JM; McCullough AE; Dueck AC; Kosiorek HE; Ocal IT; Lidner TK; Gray RJ; Wasif N; Northfelt DW; Anderson KS; Pockaj BA
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S509-15. PubMed ID: 26001860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis.
    L H Weischenfeldt K; Kirkegaard T; Rasmussen BB; Giobbie-Hurder A; Jensen MB; Ejlertsen B; Lykkesfeldt AE
    Acta Oncol; 2017 Sep; 56(9):1161-1167. PubMed ID: 28488912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated Caspase 3 Expression in Remnant Disease After Neoadjuvant Chemotherapy May Predict Outcomes of Breast Cancer Patients.
    Himuro T; Horimoto Y; Arakawa A; Matsuoka J; Tokuda E; Tanabe M; Saito M
    Ann Surg Oncol; 2016 Jul; 23(7):2235-41. PubMed ID: 26932709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.
    Yip C; Foidart P; Somja J; Truong A; Lienard M; Feyereisen E; Schroeder H; Gofflot S; Donneau AF; Collignon J; Delvenne P; Sounni NE; Jerusalem G; Noël A
    Br J Cancer; 2017 Mar; 116(6):742-751. PubMed ID: 28196064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
    Loibl S; Müller BM; von Minckwitz G; Schwabe M; Roller M; Darb-Esfahani S; Ataseven B; du Bois A; Fissler-Eckhoff A; Gerber B; Kulmer U; Alles JU; Mehta K; Denkert C
    Breast Cancer Res Treat; 2011 Nov; 130(2):477-87. PubMed ID: 21837479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
    Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
    Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer.
    Xiao M; Lou C; Xiao H; Yang Y; Cai X; Li C; Jia S; Huang Y
    Br J Surg; 2018 Jan; 105(1):75-85. PubMed ID: 29116653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
    Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
    Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
    Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
    Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
    Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
    Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
    Abd-Elazeem MA; Abd-Elazeem MA
    Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.